中国临床药理学杂志Issue(21)：2118-2120,3.DOI:10.13699/j.cnki.1001-6821.2015.21.010
伏立诺他在皮肤 T细胞淋巴瘤患者的药代动力学研究
Pharmacokinetic study of vorinostat in cutaneous T cell lymphoma patients
郑靖 1秦永平 1苗佳 1章丽 1刘雯 1舒世清 1王颖 1朱晓红1
作者信息
- 1. 四川大学 华西医院 I 期临床研究室，成都610041
- 折叠
摘要
Abstract
Objective To investigate the pharmacokinetic( PK) charac-teristics of vorinostat in cutaneous T -cell lymphoma ( CTCL ) patients after a single dose.Methods Two cases of CTCL patients were orally administered of vorinostat capsules at 200 mg or 400 mg once after break-fast.The 3 mL blood samples were collected pre-dose and at different time points.Vorinostat ( SHA ) , M2 metabolites ( M2 ) and the internal standard d5-vorinostat( d5-SHA) in serum were measured by HPLC-MS/MS method.WinNonlin 6.1 software was used to calculate the non-compartment pharmacokinetic parameters.Results After a single dose of oral administration of 200 mg and 400 mg vorinostat capsule, Cmax were 262.95 and 257.46 ng・ mL-1 , t1/2 were 1.86 and 2.52 h, tmax were 3.00 and 4.00 h, AUC0-t were 638.13 and 1503.14 ng・ mL-1・ h for SHA, respectively.Cmax were 450.88 and 652.70 ng・ mL-1 , t1/2 were 80.21 and 14.14 h, tmax was 4.00 h, AUC0-t were 2292.03 and 4848.29 ng・ mL-1・ h for M2, respectively.It was safe for the two patients to use vorinostat capsule, and there was no adverse reactions.Conclusion The individual disposition of vorinostat had a large different.关键词
伏立诺他/皮肤T细胞淋巴瘤/单次给药/药代动力学Key words
vorinostat/cutaneous T -cell lymphoma/single dose/pharmacokinetic分类
医药卫生引用本文复制引用
郑靖,秦永平,苗佳,章丽,刘雯,舒世清,王颖,朱晓红..伏立诺他在皮肤 T细胞淋巴瘤患者的药代动力学研究[J].中国临床药理学杂志,2015,(21):2118-2120,3.
